



# Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19

Jiuyang Xu <sup>1,2,3</sup> and Bin Cao <sup>2,3,4</sup>

<sup>1</sup>Tsinghua University School of Medicine, Beijing, China. <sup>2</sup>Dept of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Beijing, China. <sup>3</sup>Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China. <sup>4</sup>Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China.

Corresponding author: Bin Cao ([caobin\\_ben@163.com](mailto:caobin_ben@163.com))



Shareable abstract (@ERSpublications)

**Solid pre-clinical investigations serve as the basis for clinical research. High quality clinical trials remain the definitive measure to evaluate an interventional therapy. Clinical decisions should be independent from media and political propaganda.** <https://bit.ly/3iaNBsB>

**Cite this article as:** Xu J, Cao B. Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19. *Eur Respir J* 2022; 59: 2102002 [DOI: 10.1183/13993003.02002-2021].

This single-page version can be shared freely online.

Copyright ©The authors 2022.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

Received: 18 July 2021  
Accepted: 19 July 2021

Coronavirus disease 2019 (COVID-19) is still exerting a great influence on global health and economy. The initial fight against COVID-19 relied mainly on non-pharmacological measures, including social distancing, facial masks, active screening and isolation, *etc.* In terms of pharmacological interventions, huge progress has been made in the development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), although the appearance of several mutant variants has raised concerns for lasting immunity. The repurposing of established drugs has been another strategy to search for weapons in treatment or prophylaxis against COVID-19. Although immuno-modulating drugs, including corticosteroids, have been demonstrated to have therapeutic effects, no anti-viral medications have so far been shown to be protective.

